BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35339647)

  • 1. Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities.
    Venkataramany AS; Schieffer KM; Lee K; Cottrell CE; Wang PY; Mardis ER; Cripe TP; Chandler DS
    Ann Oncol; 2022 Jun; 33(6):578-592. PubMed ID: 35339647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers.
    Sahin I; George A; Seyhan AA
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
    Urbanski LM; Leclair N; Anczuków O
    Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive profiling of cancer neoantigens from aberrant RNA splicing.
    Wickland DP; McNinch C; Jessen E; Necela B; Shreeder B; Lin Y; Knutson KL; Asmann YW
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
    Roy Burman D; Das S; Das C; Bhattacharya R
    Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
    Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
    Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the c.793-1G > A splicing variant in CHEK2 gene as pathogenic: a case report.
    Agiannitopoulos K; Papadopoulou E; Tsaousis GN; Pepe G; Kampouri S; Kocdor MA; Nasioulas G
    BMC Med Genet; 2019 Jul; 20(1):131. PubMed ID: 31349801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative Splicing: Expanding the Landscape of Cancer Biomarkers and Therapeutics.
    Bessa C; Matos P; Jordan P; Gonçalves V
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA splicing dysregulation and the hallmarks of cancer.
    Bradley RK; Anczuków O
    Nat Rev Cancer; 2023 Mar; 23(3):135-155. PubMed ID: 36627445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
    Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities.
    Bemmo A; Dias C; Rose AA; Russo C; Siegel P; Majewski J
    PLoS One; 2010 Aug; 5(8):e11981. PubMed ID: 20700505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases.
    Mercatante DR; Sazani P; Kole R
    Curr Cancer Drug Targets; 2001 Nov; 1(3):211-30. PubMed ID: 12188880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
    Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
    Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA Splicing and Cancer.
    Wang E; Aifantis I
    Trends Cancer; 2020 Aug; 6(8):631-644. PubMed ID: 32434734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entropy measures quantify global splicing disorders in cancer.
    Ritchie W; Granjeaud S; Puthier D; Gautheret D
    PLoS Comput Biol; 2008 Mar; 4(3):e1000011. PubMed ID: 18369415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA splicing: a dual-edged sword for hepatocellular carcinoma.
    Kashyap A; Tripathi G; Tripathi A; Rao R; Kashyap M; Bhat A; Kumar D; Rajhans A; Kumar P; Chandrashekar DS; Mahmood R; Husain A; Zayed H; Bharti AC; Kashyap MK
    Med Oncol; 2022 Aug; 39(11):173. PubMed ID: 35972700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long Non-Coding RNA Expression Levels Modulate Cell-Type-Specific Splicing Patterns by Altering Their Interaction Landscape with RNA-Binding Proteins.
    Porto FW; Daulatabad SV; Janga SC
    Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31390792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies.
    Rizzacasa B; Morini E; Pucci S; Murdocca M; Novelli G; Amati F
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival.
    Renshaw J; Orr RM; Walton MI; Te Poele R; Williams RD; Wancewicz EV; Monia BP; Workman P; Pritchard-Jones K
    Mol Cancer Ther; 2004 Nov; 3(11):1467-84. PubMed ID: 15542786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splice variants of MDM2 in oncogenesis.
    Rosso M; Okoro DE; Bargonetti J
    Subcell Biochem; 2014; 85():247-61. PubMed ID: 25201199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.